359442-67-4

Usage

Uses

Used in Organic Synthesis:
N-(Allyloxy)-2-nitrobenzenesulfonamide is used as a reagent in organic synthesis for its ability to participate in nucleophilic aromatic substitution and palladium-catalyzed cross-coupling reactions. Its reactivity is attributed to the presence of the nitro group, which can be reduced or further functionalized to yield a range of valuable intermediates and final products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(Allyloxy)-2-nitrobenzenesulfonamide is utilized as a building block in the synthesis of various pharmaceuticals. Its unique chemical properties allow for the creation of novel drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
N-(Allyloxy)-2-nitrobenzenesulfonamide also finds application in the agrochemical industry, where it is employed in the synthesis of agrochemicals. Its versatility in organic reactions enables the development of new compounds with potential use in crop protection and pest control.
Used in Dye Industry:
In the dye industry, N-(Allyloxy)-2-nitrobenzenesulfonamide is used in the synthesis of dyes, where its chemical properties contribute to the development of new colorants with specific characteristics, such as improved colorfastness or solubility.
Used in Therapeutic Research:
N-(Allyloxy)-2-nitrobenzenesulfonamide has been studied for its potential anti-inflammatory and anti-tumor properties, indicating its promise as a therapeutic agent. Its use in this area is still in the research phase, but it holds potential for future development as a treatment for various conditions.

Upstream product

• 38945-21-0 O-allylhydroxylamine hydrochloride 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 

Relevant academic research and scientific papers

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inhibitors (BLIs) can be administered in combination with β-lactam antibiotics to negate the action of the β-lactamases, thereby restoring activity of the β-lactam. Newly developed BLIs offer some advantage over older BLIs in terms of enzymatic spectrum but are limited to the intravenous route of administration. Reported here is a novel, orally bioavailable diazabicyclooctane (DBO) β-lactamase inhibitor. This new DBO, ETX1317, contains an endocyclic carbon-carbon double bond and a fluoroacetate activating group and exhibits broad spectrum activity against class A, C, and D serine β-lactamases. The ester prodrug of ETX1317, ETX0282, is orally bioavailable and, in combination with cefpodoxime proxetil, is currently in development as an oral therapy for multidrug resistant and carbapenem-resistant Enterobacterales infections.

BETA-LACTAMASE INHIBITOR COMPOUNDS

The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta- lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.

HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS

The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R 2, R 3 and R 4 are described herein.

O-Protected N-(2-Nitrophenylsulfonyl)hydroxylamines: Novel Reagents for the Synthesis of Hydroxamates

Preparative methods for novel O-protected N-(2-nitrophenylsulfonyl)hydroxylamines (8a-e) are described. Their versatility as intermediates en route to polyhydroxamates is examplified by the synthesis of a non-amide DFO analog 22.